St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.
Clin Exp Allergy. 2023 May;53(5):495-510. doi: 10.1111/cea.14301. Epub 2023 Mar 22.
Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition with an unpredictable clinical course, associated with a significant impact on quality of life. The pathophysiology of AD involves a complex interplay between impaired skin barrier function, immune dysregulation, genetic susceptibility and environmental factors. Advances in understanding of the immunological mechanisms that underpin AD have heralded the recognition of multiple novel therapeutic targets to bolster the systemic treatment armamentarium for patients with severe AD. This review examines current and future directions of non-biologic systemic treatments for AD, with a focus on their mechanism of action, efficacy and safety, and the key considerations to help inform treatment decisions. We summarize new developments in small molecule systemic therapies which have the potential to further advance our management of AD in this new era of precision medicine.
特应性皮炎(AD)是一种常见的慢性炎症性皮肤病,其临床病程不可预测,对生活质量有重大影响。AD 的病理生理学涉及受损的皮肤屏障功能、免疫失调、遗传易感性和环境因素之间的复杂相互作用。对支持 AD 患者系统治疗武器库的免疫机制的理解的进步预示着多个新的治疗靶点的出现。这篇综述探讨了 AD 的非生物系统治疗的现状和未来方向,重点是它们的作用机制、疗效和安全性,以及帮助做出治疗决策的关键考虑因素。我们总结了小分子系统疗法的新进展,这些进展有可能在精准医学的新时代进一步推进我们对 AD 的管理。